ANI Pharmaceuticals (NASDAQ:ANIP) VP Sells $41,015.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 500 shares of the firm’s stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $82.03, for a total transaction of $41,015.00. Following the transaction, the vice president directly owned 77,890 shares in the company, valued at $6,389,316.70. This represents a 0.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Meredith Cook also recently made the following trade(s):

• On Wednesday, May 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $78.16, for a total transaction of $39,080.00.
• On Monday, April 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $77.95, for a total value of $38,975.00.

ANI Pharmaceuticals Price Performance

NASDAQ:ANIP traded up $0.61 during trading hours on Monday, reaching $82.29. 293,873 shares of the company were exchanged, compared to its average volume of 393,012. The business has a 50 day moving average of $79.72 and a 200 day moving average of $79.41. ANI Pharmaceuticals, Inc. has a 1-year low of $62.14 and a 1-year high of $99.50. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.12 and a quick ratio of 2.52. The company has a market capitalization of $1.87 billion, a P/E ratio of 20.83 and a beta of 0.44.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.77. The firm had revenue of $237.46 million during the quarter, compared to analysts’ expectations of $207.63 million. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The company’s quarterly revenue was up 20.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.70 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Research analysts forecast that ANI Pharmaceuticals, Inc. will post 8.07 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Weiss Ratings restated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday, June 1st. Finally, Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Five research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, ANI Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $107.33.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of institutional investors have recently modified their holdings of ANIP. Maryland State Retirement & Pension System boosted its stake in ANI Pharmaceuticals by 5.4% in the fourth quarter. Maryland State Retirement & Pension System now owns 2,613 shares of the specialty pharmaceutical company’s stock valued at $206,000 after buying an additional 134 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in ANI Pharmaceuticals by 1.5% during the first quarter. The Manufacturers Life Insurance Company now owns 9,577 shares of the specialty pharmaceutical company’s stock worth $736,000 after acquiring an additional 143 shares in the last quarter. Illinois Municipal Retirement Fund lifted its holdings in shares of ANI Pharmaceuticals by 1.7% in the third quarter. Illinois Municipal Retirement Fund now owns 8,538 shares of the specialty pharmaceutical company’s stock worth $782,000 after acquiring an additional 145 shares during the last quarter. CANADA LIFE ASSURANCE Co boosted its stake in shares of ANI Pharmaceuticals by 1.0% in the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company’s stock valued at $1,267,000 after purchasing an additional 198 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund boosted its stake in shares of ANI Pharmaceuticals by 5.1% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 4,086 shares of the specialty pharmaceutical company’s stock valued at $323,000 after purchasing an additional 200 shares in the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.